entertainment -WSS

entertainment

author：leisure time 2025-09-06 03:53:02 - browse：45731

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Cancer, immunology, HIV research ensnared in fetal tissue politics

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

This gene therapy has record $4.25 million price. It's saved children.

NIH documents show early flaws of $1.6 billion long Covid program

Asbestos ban is immediate, but health effects will linger for decades

Diabetes management: Digital health tools fall short, study says

Cord blood banking comes at a high cost to babies

focus

entertainment

entertainment

Continuity nursing helped my family in our darkest PICU moments

Chinese researcher claims birth of first gene

United colonoscopy coverage change 'may cost lives,' doctors say

At ASCO, AstraZeneca reports strong data for breast cancer drug

Medicare proposal to cover medical devices draws a mixed reaction

Let's speed up science by embracing open access publishing

Bright Health sells Medicare Advantage business to Molina

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to increase colonoscopy rates? Looks like an AI can help

leisure time

FDA's Pazdur wants cancer trials to range beyond China alone

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Testing GLP

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Erich Jarvis studies song birds to learn about human stuttering

Texas board proposes rules on abortion law emergency exemption

leisure time

entertainment

focus

focus